Table of Contents
PITTSBURGH — Mylan N.V. has launched fenofibrate tablets 40 mg and 120 mg, a cholesterol-lowering drug, in the United States.
Mylan said Wednesday that its fenofibrate product is a generic version of Fenoglide tablets from Santarus.
Fenofibrate tablets are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides and apolipoprotein B to increase high-density lipoprotein in adults with primary hypercholesterolemia or mixed dyslipidemia.
U.S. sales of fenofibrate tablets (40 mg and 120 mg) totaled approximately $28.6 million for the 12 months ended April 30, according to IMS Health data reported by Mylan.
